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T-Helper 17 Cells in Psoriatic Plaques 
and Additional Genetic Links 
between IL-23 and Psoriasis
Andrew Blauvelt1,2
T-helper 17 (Th17) cells are a newly appreciated T-cell subset, distinct from both 
Th1 and Th2 cells, that have been implicated in the pathogenesis of psoriasis and 
other autoimmune inflammatory diseases (Figure 1) (Fitch et al., 2007; Kastelein 
et al., 2007). IL-23 stimulates survival and proliferation of Th17 cells and thus 
serves as a key master cytokine regulator for these diseases. 
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In psoriasis lesions, IL-23 is overpro-
duced by dendritic cells (Lee et al., 
2004; Wilson et al., 2007) and kerati-
nocytes (Piskin et al., 2006), and this 
cytokine stimulates Th17 cells within 
dermis to make “Th17 cytokines,” 
which include IL-17A, IL-17F, tumor 
necrosis factor (TNF)-α, IL-21, and IL-
22 (Figure 1) (Fitch et al, 2007; Kastelein 
et al, 2007). IL-22—rather than IL-17A, 
for which Th17 cells are named—is 
emerging as the prototypic Th17 cyto-
kine that is perhaps most specific for 
Th17 cells (Liang et al., 2006). Because 
it is a potent stimulus for keratinocyte 
proliferation (Wolk et al., 2006; Sa et 
al., 2007; Zheng et al., 2007), IL-22 has 
also gained prominence in the patho-
genesis of psoriasis as a key effector 
Th17 cytokine (Fitch et al., 2007).
In this issue, Krueger and his group of 
investigators at Rockefeller University 
show for the first time the discrete pres-
ence of IL-17A-producing cells within 
the dermis of psoriatic plaques (Lowes 
et al., 2008). Previously, Krueger’s and 
other groups had found increased lev-
els of mRNA specific for the T-helper 
17 (Th17) cytokines mentioned above, 
as well as increased mRNA levels for 
the IL-23 subunits, IL-12/23p40 and 
IL-23p19, in psoriasis (Lee et al., 2004; 
Chan et al., 2006; Wilson et al., 2007). 
To demonstrate IL-17A+ cells within 
psoriatic plaques, skin was biopsied, 
epidermis was separated from dermis 
using dispase, and leukocytes were 
allowed to spontaneously “crawl-out” 
of dermis placed into culture. These 
cells were then collected; stimulated 
for 4 hours with phorbol ester and 
ionomycin; labeled with antibodies 
directed against IL-17A, IFN-γ, and 
TNF-α; and analyzed by flow cytome-
try. Psoriasis plaque dermis contained a 
mean of 6.2% of cells secreting IL-17A, 
whereas dermis from normal-appearing 
skin contained a mean of 0.5% of cells 
making IL-17A. Dermal cells co-secret-
ing IL-17A and TNF-α (5.1%) and der-
mal cells co-secreting IL-17A and IFN-γ 
(1.9%) were also significantly elevated 
in psoriasis as compared with normal-
appearing skin (0.2 and 0.1%, respec-
tively). The level of cells producing 
IFN-γ alone was statistically not higher 
in psoriatic dermis when compared 
with normal dermis. Taken together, 
these results suggest that there is a 
greater propensity for IL-17A-produc-
ing cells, rather than IFN-γ-producing 
cells, to be present in psoriatic plaques 
when compared to healthy skin. In a 
quantifiable manner, Th17 cytokine 
mRNA data in psoriatic plaques have 
now been linked with actual numbers 
of cells producing these cytokines with-
in diseased tissue.
One caveat of this work is that it has 
become clear that IL-17A production 
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alone does not necessarily correlate 
with the presence of a Th17 cell. In 
addition to Th17 cells, IL-17A can 
be produced by a subset of Th1 cells 
(Acosta-Rodriguez et al., 2007), natu-
ral killer T cells (Michel et al., 2007), 
γδ T cells (Lockhart et al., 2006), and 
dendritic cells (Coury et al., 2008). It 
will be important to perform additional 
multiparameter flow cytometric stud-
ies to more precisely identify the exact 
nature of the IL-17A-producing cells in 
psoriasis. IL-22, as mentioned above, 
may be a more specific marker for Th17 
cells. Thus, future coexpression and 
localization studies examining both 
IL-17A- and IL-22-secreting cells in 
psoriatic plaques will add other impor-
tant pieces to the evolving character-
ization of the IL-23/Th17 inflammatory 
pathway in psoriasis.
In another paper in this issue, the 
genetics underpinning susceptibility to 
or protection from psoriasis was exam-
ined (Nair et al., 2008). Elder and his 
colleagues at the University of Michigan 
examined a cohort of North American 
and German Caucasians (1,810 pso-
riatics, 2,522 controls, and 509 
pedigrees) for polymorphisms in a 
subset of IL-23- and IL-12-related 
genes, including those that encode for 
IL-23p19, IL-12/23p40, IL-12p35, 
IL-23R, IL-12Rβ1, and IL-12Rβ2. The 
choice of genes studied is important 
because IL-23 is a heterodimeric pro-
tein that consists of the unique IL-23p19 
subunit paired with a second subunit 
called IL-12/23p40, whereas IL-12 is 
a related heterodimer consisting of 
the IL-12/23p40 subunit and a subunit 
called IL-12p35 (Figure 2) (Kastelein et 
al., 2007). The receptors for IL-23 and 
IL-12 are also related heterodimers; the 
IL-23 receptor consists of IL-23R and 
IL-12Rβ1 subunits, whereas the IL-12 
receptor is composed of IL-12Rβ1 and 
IL-12Rβ2 subunits (Figure 2) (Kastelein 
et al., 2007). The conclusion of Nair 
and colleagues’ paper is that certain 
polymorphisms in genes that encode 
for IL-12/23p40 and IL-23R promote 
susceptibility to psoriasis, whereas 
other polymorphisms in the same two 
genes confer protection from devel-
oping psoriasis. This work confirms 
genetic associations first reported in 
2002 for IL-12/23p40 and subsequent-
ly in two studies on IL-12/23p40 and 
IL-23R (Capon et al., 2007; Cargill et 
al., 2007). Thus, genes that encode for 
IL-12/23p40 and IL-23R are clearly 
linked to psoriasis.
At least three ingredients are still 
lacking in the overall picture of genet-
ics studies and psoriasis. First, the 
IL-12/23p40 and IL-23R genetics data 
in humans have not been compared 
and contrasted with functional data 
from biologic experiments. It is predict-
ed that these in vitro studies will dem-
onstrate that certain genetic changes 
in IL-12/23p40 and IL-23R will lead to 
enhanced IL-23 production and IL-23 
receptor-mediated signaling and thus 
be correlative with psoriasis suscep-
tibility in humans. In contrast, other 
mutations that result in decreased IL-23 
production and IL-23 receptor-mediated 
signaling in vitro are predicted 
to be associated with protection 
from developing psoriasis in indi-
viduals who carry these particular 
polymorphisms. Second, geno-
type–phenotype studies have yet to 
be completed, although many are 
underway. For instance, will certain 
IL-12/23p40 and IL-23R polymor-
phisms correlate with certain disease 
presentations (e.g., guttate vs. pustular 
psoriasis) or with severity of disease? 
Third, do the polymorphisms described 
by Elder and others confer therapeu-
tic responsiveness to drugs that target 
IL-12/23p40, such as ustekinumab 
(Krueger et al., 2007) and ABT-874 
(Kimball et al., 2008)? Such pharma-
cogenomic studies now appear to be 






















Figure 1. Th17 cells are distinct from Th1 cells, differentiate in the presence of IL-1 and IL-6, proliferate 
in response to IL-23, and secrete a characteristic set of cytokines. (Modified from Fitch et al., 2007.)











Figure 2. Schematic of the related heterodimers 
IL-23 and IL-12 and their related heterodimeric 
cytokine receptors, indicating (in red circles) the 
subunits where polymorphisms in genes encoding 
these proteins have been linked to development 
of psoriasis. (Modified from Blauvelt, 2007.)
|New genetic and immunologic studies suggest new therapeutic 
targets in psoriasis.
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In the ongoing discussion of whether 
psoriasis represents a “Th1 disease” (as 
has been espoused for many years), a 
“Th17 disease,” or some combination 
of both, the most recent data emerging 
from many investigators studying vari-
ous aspects of this immunologic puzzle 
suggest that IL-23 and Th17 cells are 
key mediators of disease pathogenesis 
(Fitch et al., 2007; Lowes et al., 2007; 
Nickoloff, 2007). In other words, IL-
23, which makes Th17 cells survive 
and proliferate, has emerged as a mas-
ter cytokine in the new paradigm of 
psoriasis pathogenesis. Although the 
IL-12/23p40 genetic data discussed 
above do not clearly implicate IL-23 
more than IL-12, or vice versa, the 
IL-23R genetic data clearly point to 
IL-23 as a central cytokine in psoria-
sis (Capon et al., 2007; Cargill et al., 
2007; Nair et al., 2008). Similarly, 
psoriasis patients treated with mono-
clonal antibodies directed against 
IL-12/23p40 demonstrate substan-
tial clinical responses (Krueger et 
al., 2007; Kimball et al., 2008), yet 
the relative importance of IL-23 vs. 
IL-12 in disease maintenance is not dis-
tinguished. Of note, however, pharma-
ceutical companies’ interest in drugs 
that specifically target IL-23 and Th17 
cells is high. New-age biologics that 
specifically block components of the 
IL-23/Th17 inflammatory pathway, 
such as IL-23p19, IL-23R, IL-17A, and 
IL-22, are examples of compounds that 
are making their way through the phar-
maceutical industry’s developmental 
pipelines. It will be interesting to learn 
whether the drugs that are targeted 
more to the IL-23/Th17 cell inflam-
matory pathway will be as effective 
for psoriasis as the less selective anti- 
IL-12/23p40 monoclonal antibodies. It 
is predicted that inhibition of IL-23 will 
lead to death of Th17 cells and long-
lasting abrogation of psoriasis. Finally, 
determining the biologic effects of such 
drugs (both dual IL-23/IL-12 inhibitors 
and selective IL-23 inhibitors) on normal 
cellular processes and examining over-
all drug safety profiles will be important 
to ensure adequate risk–benefit ratios 
for patients.
It is an exciting time to be working 
in psoriasis. Recent pioneering research 
in cellular immunology has led to 
the discovery of IL-23 and Th17 cells 
(Kastelein et al., 2007). These seminal 
studies, in combination with new infor-
mation on murine models of psoriasis 
(Gudjonsson et al., 2007), data from 
human skin affected by psoriasis (Lowes 
et al., 2008), advances in genetics (Nair 
et al., 2008), and the development of 
novel targeted therapeutics for patients 
with psoriasis (Krueger et al., 2007; 
Kimball et al., 2008), have converged 
into a fertile mix of new and useful 
knowledge about psoriasis. Although 
much work remains to be done, inves-
tigators studying psoriasis now appear 
poised to unravel many of the remain-
ing mysteries of this enigmatic disease.
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“Outside-to-Inside” (and Now Back 
to “Outside”) Pathogenic Mechanisms 
in Atopic Dermatitis
Peter M. Elias1,2 and Martin Steinhoff 2,3
The pathogenesis of atopic dermatitis (AD) has been attributed largely to 
abnormalities in the adaptive immune system, with key roles played by T-help-
er 1(Th1)/Th2 cell dysregulation, IgE production, dendritic cell signaling, and 
mast-cell hyperactivity, resulting in the pruritic, inflammatory dermatosis that 
characterizes AD (Leung et al., 2004). Accordingly, therapy has been focused 
on ameliorating Th2-mediated inflammation and pruritus (e.g., Leung, 2000). 
Indeed, there is emerging evidence that inflammation in AD results first from 
inherited and acquired insults that converge to alter epidermal structure and 
function, followed by immune system activation, which in turn has negative 
consequences for skin-barrier homeostasis. This cycle comprises an “outside–
inside–outside” model of AD pathogenesis (Elias et al., in press).
Journal of Investigative Dermatology (2008), 128, 1067–1070. doi:10.1038/jid.2008.88
The epidermis generates an impres-
sive set of critical defensive functions 
(Elias, 2005; Elias and Choi, 2005) 
that include the permeability barrier, 
allowing survival in a potentially des-
iccating external environment, and an 
antimicrobial barrier, which simulta-
neously encourages colonization by 
nonpathogenic “normal” flora while 
resisting growth of microbial patho-
gens (Elias, 2007). The permeability 
barrier resides in the stratum corneum 
(SC), where multiple layers of anucleate 
corneocytes are embedded in an extra-
cellular matrix, enriched in ceramides 
(Cer), cholesterol, and free fatty acids, 
arranged as planar lamellar sheets 
(Elias and Menon, 1991). These lipids, 
as well as an assortment of hydrolases 
important for lipid processing and des-
quamation and at least two key anti-
microbial peptides (Aberg et al., 2007, 
and references cited therein), are deliv-
ered to the extracellular matrix through 
secretion of epidermal lamellar body 
contents. Whereas lamellar body–
derived proteases and their inhibitors 
orchestrate the orderly digestion of cor-
neodesmosomes, allowing cells to shed 
invisibly at the skin surface (Brattsand 
et al., 2005; Stefansson et al., 2008), 
the lipid-processing enzymes (β-gluco-
cerebrosidase, acidic sphingomyelin-
ase, and secretory phospholipase A2) 
generate the Cer and free fatty acids 
that, along with cholesterol, form the 
extracellular lamellar membrane (Elias 
and Menon, 1991). Thus, proteases as 
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well as extracellular enzymes may ulti-
mately be involved in the pathophysiol-
ogy of eczema and pruritus.
Based primarily on the strong asso-
ciation of inherited abnormalities in 
filaggrin (FLG) expression, atopic der-
matitis (AD), at least in Euro-Americans, 
is now increasingly considered a prima-
ry disorder of SC structure and function 
(Hudson, 2006; Irvine and McLean, 
2006; Palmer et al., 2006; Smith et al., 
2006; Weidinger et al., 2006). Thus, 
AD can be considered a disease of pri-
mary barrier failure, characterized by 
both a defective permeability (Proksch 
et al., 2006, and references therein) 
and antimicrobial function (Baker, 
2006; Boguniewicz and Leung, 2006). 
Although both of these abnormalities 
are well-recognized features of AD, 
they have been widely assumed to 
reflect downstream consequences of a 
primary immunologic abnormality (the 
historical inside–outside view of AD 
pathogenesis). We and others have long 
proposed that the permeability-bar-
rier abnormality in AD is not merely an 
epiphenomenon but rather the “driver” 
of disease activity (i.e., the reverse, 
outside–inside view of disease patho-
genesis) (Elias and Feingold, 2001), 
because (1) the extent of the permeabil-
ity-barrier abnormality parallels sever-
ity of disease phenotype in AD, (2) both 
clinically uninvolved skin sites and skin 
cleared of inflammation for as long as 
5 years continue to display significant 
barrier abnormalities, (3) emollient 
therapy comprises effective ancillary 
therapy, and (4) specific replacement 
therapy, which targets the prominent 
lipid abnormalities that account for 
the barrier abnormality in AD, not only 
corrects the permeability-barrier abnor-
mality but also comprises effective anti-
inflammatory therapy for AD (Chamlin 
et al., 2002; Figure 1).
Still, how loss of FLG (an intracellular 
protein) provokes a permeability-bar-
|Inﬂammation in AD may begin with insults from without.
